Internal Medicine, Medical Oncology · Dallas, TX
NPI
1306884333
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
3410 Worth St
Dallas, TX, 75246
Phone (214) 370-1000
Medicare paid, 2024
$1.3M
72,795 services
Medicare patients, 2024
421
Average age 74
Drug cost, 2024
$818K
219 prescriptions
Company payments, 2025
$94.33
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mark W Walberg was code J9271 (injection, pembrolizumab, 1 mg), 9,000 times for 30 patients. In total Mark W Walberg billed 72,795 services in 165 codes, and Medicare paid $1.3M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-10-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,000 | 30 | $44.68 | $402K |
| J1756 Injection, iron sucrose, 1 mg | Office | 7,000 | 30 | $0.18 | $1,242 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 6,300 | 38 | $0.11 | $697 |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,999 | 36 | $0.10 | $397 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 3,060 | 15 | $38.76 | $119K |
| J9267 Injection, paclitaxel, 1 mg | Office | 2,894 | 16 | $0.08 | $239 |
| J1930 Injection, lanreotide, 1 mg | Office | 1,680 | 13 | $38.03 | $64K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 960 | 78 | $0.09 | $87.37 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 580 | 51 | $0.73 | $426 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 460 | 32 | $0.26 | $119 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 263 | 16 | $3.66 | $961 |
| 96367 Intravenous Infusion, Hydration | Office | 187 | 90 | $22.11 | $4,134 |
| 96413 Chemotherapy Administration | Office | 176 | 134 | $101.18 | $18K |
| J9190 Injection, fluorouracil, 500 mg | Office | 175 | 20 | $2.38 | $417 |
| 96375 Injection Administration | Office | 158 | 87 | $12.02 | $1,899 |
By year: 2022 $1.5M for 82,439 services; 2023 $1.6M for 98,109 services; 2024 $1.3M for 72,795 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80053 Clinical Chemistry | 89 | 33 | $10.35 | $921 |
| 36415 Venipuncture Blood Collection | 87 | 32 | $8.65 | $753 |
| 85025 Blood Count | 82 | 33 | $7.53 | $618 |
| 84443 Clinical Chemistry | 21 | 11 | $16.46 | $346 |
Medicare prescription drug claims, 2024
In 2024, the drug Mark W Walberg prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 36 prescriptions and refills. In total Mark W Walberg wrote 219 Medicare prescriptions that cost $818K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 36 | 36 | 16 | $920 |
| Lenvima Lenvatinib Mesylate | 16 | 16 | Under 11 | $388K |
| Prochlorperazine Maleate Generic | 16 | 16 | Under 11 | $209 |
| Prednisone Generic | 12 | 22 | Under 11 | $87.3 |
| Sorafenib Sorafenib Tosylate | 11 | 11 | Under 11 | $172K |
Brand drugs: 33 claims; generic drugs: 186 claims; opioid claims: 43.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mark W Walberg $94.33 ($94.33 in general payments such as food, travel and fees) from 3 companies. The largest payer was Janssen Scientific Affairs, LLC with $50.8.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.